Viking Therapeutics Inc (VKTX) Sees Significant Increase in Short Interest
Viking Therapeutics Inc (NASDAQ:VKTX) was the recipient of a significant increase in short interest in the month of January. As of January 12th, there was short interest totalling 1,965,269 shares, an increase of 48.1% from the December 29th total of 1,326,621 shares. Based on an average daily trading volume, of 833,219 shares, the days-to-cover ratio is presently 2.4 days. Approximately 8.1% of the company’s shares are short sold.
Several large investors have recently modified their holdings of the company. Sabby Management LLC acquired a new position in shares of Viking Therapeutics during the second quarter worth approximately $525,000. Sphera Funds Management LTD. acquired a new position in shares of Viking Therapeutics during the third quarter worth approximately $554,000. Victory Capital Management Inc. purchased a new stake in Viking Therapeutics in the 4th quarter valued at $791,000. Virtu KCG Holdings LLC purchased a new stake in Viking Therapeutics in the 2nd quarter valued at $124,000. Finally, Creative Planning raised its position in Viking Therapeutics by 600.0% in the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 60,000 shares during the last quarter. 5.81% of the stock is currently owned by institutional investors.
Several brokerages have issued reports on VKTX. Maxim Group set a $8.00 price target on Viking Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 12th. ValuEngine lowered Viking Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Roth Capital began coverage on Viking Therapeutics in a research report on Tuesday, November 21st. They set a “buy” rating and a $5.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Viking Therapeutics in a research report on Friday, November 10th.
Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). equities research analysts predict that Viking Therapeutics will post -0.86 EPS for the current fiscal year.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.